| Phase 11 trial |
|
Phase 1
|
NCT03377478 |
Jul 2019 → Sep 2021 |
hepatitis C virus infection |
Pablo Sanchez |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT03724149 |
Dec 2018 → Dec 2021 |
lung disorder |
University of Pennsylvania |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT04075916 |
Jun 2021 → Jul 2025 |
end stage renal failure |
University of Pennsylvania |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03383419 |
Mar 2018 → Dec 2026 expected |
heart failure |
Baylor Research Institute |
Recruiting
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT02825212 |
Feb 2016 → Jul 2019 |
chronic hepatitis C virus infection, cryoglobulinemia |
Icahn School of Medicine at Mount Sinai |
Completed
|
No outcome recorded
|
| Phase 44 trials |
|
Phase 4
|
NCT07098481 |
Sep 2025 → Dec 2027 expected |
hepatitis C virus infection |
ANRS, Emerging Infectious Diseases |
Not yet recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT03625687 |
Feb 2019 → Apr 2022 |
hepatitis C virus infection, respiratory failure |
Massachusetts General Hospital |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 4
|
NCT03549312 |
Feb 2018 → Jul 2020 |
HIV infectious disease, chronic hepatitis C virus infection, coinfection, metabolic bone disorder +1 |
Saskatchewan Health Authority - Regina Area |
Unknown
|
No outcome recorded
|
|
Phase 4
|
NCT03207399 |
Sep 2017 → Mar 2019 |
chronic hepatitis C virus infection |
Duke University |
Terminated
|
No outcome recorded
Stop: Enrollment |